Immediate Impact
46 standout
Citing Papers
The hallmarks of cancer immune evasion
2024 Standout
Current and future immunotherapeutic approaches in pancreatic cancer treatment
2024 Standout
Works of H. Ma being referenced
Multicenter phase Ib trial in the U.S. of salvage CT041 CLDN18.2-specific chimeric antigen receptor T-cell therapy for patients with advanced gastric and pancreatic adenocarcinoma.
2022
432 Evaluation of novel anti-TIGIT antibody M6223 as a single agent and in combination with avelumab on human natural killer (NK) cell cytotoxicity
2022
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| H. Ma | 233 | 81 | 99 | 91 | 35 | 384 | |
| A. Haas | 36 | 59 | 93 | 139 | 31 | 458 | |
| R. D. Wilkinson | 103 | 13 | 53 | 53 | 21 | 389 | |
| K. Yoshikawa | 47 | 73 | 17 | 48 | 28 | 398 | |
| Laura Galeotti | 111 | 61 | 8 | 21 | 24 | 408 | |
| Stephen Howard | 119 | 63 | 16 | 9 | 26 | 451 | |
| Keiichi Sakurai | 63 | 70 | 37 | 16 | 33 | 392 | |
| Shinichiro Koyama | 72 | 54 | 24 | 64 | 35 | 402 | |
| Victor Stoica | 25 | 185 | 29 | 35 | 47 | 414 | |
| Sultan Mahmood | 153 | 15 | 6 | 49 | 48 | 350 | |
| Robert B. Adams | 39 | 31 | 11 | 21 | 44 | 377 |
All Works
Login with ORCID to disown or claim papers
Loading papers...